Abstract
Background/objectives Diagnosing the invasiveness of intraductal papillary mucinous neoplasms (IPMNs) is difficult, especially by blood test. Alterations in serum glycan profiles have been reported for several cancers, but changes in serum glycan profiles have not been investigated in patients with IPMNs. The objectives of this study were to determine the serum N-glycan profile and to investigate its clinical utility in patients with IPMNs. Methods We measured serum N-glycan profiles in 79 patients with IPMNs, including 13 invasive IPMNs, by performing comprehensive glycome analysis and assessed the relationship between N-glycan changes and clinical parameters. Results Seventy glycans were identified and their expression profiles were significantly different depending on the cyst size, the presence of an enhancing solid component, and the histological grade of the IPMN. Nine glycans were highly expressed in patients with invasive IPMNs. The glycan m/z 3195, which is a fucosylated tri-antennary glycan, had the highest diagnostic value for distinguishing invasive IPMNs from non-invasive IPMNs (area under the receiver operating characteristic curve = 0.803). Multivariate analyses revealed high levels of m/z 3195 [odds ratio (OR), 20.5; 95% confidence interval (CI) 2.60-486.4] and the presence of enhancing solid components (OR, 35.8; 95% CI, 5.39-409.6) were significant risk factors for invasive IPMNs. Conclusions We performed a comprehensive evaluation of the changes in serum N-glycan profiles in patients with IPMNs for the first time. We determined that increased expression of fucosylated complex-type glycans, especially m/z 3195, is a potential marker for invasive IPMNs.
| Original language | English |
|---|---|
| Pages (from-to) | 432-438 |
| Number of pages | 7 |
| Journal | Pancreatology |
| Volume | 15 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Jul 1 2015 |
Fingerprint
Keywords
- Biological markers
- Fucosylation
- Glycomics
- Intraductal papillary mucinous neoplasm
- Malignancy
- Pancreas
ASJC Scopus subject areas
- Endocrinology
- Endocrinology, Diabetes and Metabolism
- Hepatology
Cite this
Serum N-glycan profiles in patients with intraductal papillary mucinous neoplasms of the pancreas. / Akimoto, Yutaka; Nouso, Kazuhiro; Katou, Hironari; Miyahara, Koji; Dohi, Chihiro; Morimoto, Yuki; Kunugasa, Hideaki; Tomoda, Takeshi; Yamamoto, Naoki; Tsutsumi, Koichiro; Kuwaki, Kenji; Ohnishi, Hideki; Ikeda, Fusao; Nakamura, Shinichiro; Shiraha, Hidenori; Takaki, Akinobu; Okada, Hiroyuki; Amano, Maho; Nishimura, Shin Ichiro; Yamamoto, Kazuhide.
In: Pancreatology, Vol. 15, No. 4, 01.07.2015, p. 432-438.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Serum N-glycan profiles in patients with intraductal papillary mucinous neoplasms of the pancreas
AU - Akimoto, Yutaka
AU - Nouso, Kazuhiro
AU - Katou, Hironari
AU - Miyahara, Koji
AU - Dohi, Chihiro
AU - Morimoto, Yuki
AU - Kunugasa, Hideaki
AU - Tomoda, Takeshi
AU - Yamamoto, Naoki
AU - Tsutsumi, Koichiro
AU - Kuwaki, Kenji
AU - Ohnishi, Hideki
AU - Ikeda, Fusao
AU - Nakamura, Shinichiro
AU - Shiraha, Hidenori
AU - Takaki, Akinobu
AU - Okada, Hiroyuki
AU - Amano, Maho
AU - Nishimura, Shin Ichiro
AU - Yamamoto, Kazuhide
PY - 2015/7/1
Y1 - 2015/7/1
N2 - Background/objectives Diagnosing the invasiveness of intraductal papillary mucinous neoplasms (IPMNs) is difficult, especially by blood test. Alterations in serum glycan profiles have been reported for several cancers, but changes in serum glycan profiles have not been investigated in patients with IPMNs. The objectives of this study were to determine the serum N-glycan profile and to investigate its clinical utility in patients with IPMNs. Methods We measured serum N-glycan profiles in 79 patients with IPMNs, including 13 invasive IPMNs, by performing comprehensive glycome analysis and assessed the relationship between N-glycan changes and clinical parameters. Results Seventy glycans were identified and their expression profiles were significantly different depending on the cyst size, the presence of an enhancing solid component, and the histological grade of the IPMN. Nine glycans were highly expressed in patients with invasive IPMNs. The glycan m/z 3195, which is a fucosylated tri-antennary glycan, had the highest diagnostic value for distinguishing invasive IPMNs from non-invasive IPMNs (area under the receiver operating characteristic curve = 0.803). Multivariate analyses revealed high levels of m/z 3195 [odds ratio (OR), 20.5; 95% confidence interval (CI) 2.60-486.4] and the presence of enhancing solid components (OR, 35.8; 95% CI, 5.39-409.6) were significant risk factors for invasive IPMNs. Conclusions We performed a comprehensive evaluation of the changes in serum N-glycan profiles in patients with IPMNs for the first time. We determined that increased expression of fucosylated complex-type glycans, especially m/z 3195, is a potential marker for invasive IPMNs.
AB - Background/objectives Diagnosing the invasiveness of intraductal papillary mucinous neoplasms (IPMNs) is difficult, especially by blood test. Alterations in serum glycan profiles have been reported for several cancers, but changes in serum glycan profiles have not been investigated in patients with IPMNs. The objectives of this study were to determine the serum N-glycan profile and to investigate its clinical utility in patients with IPMNs. Methods We measured serum N-glycan profiles in 79 patients with IPMNs, including 13 invasive IPMNs, by performing comprehensive glycome analysis and assessed the relationship between N-glycan changes and clinical parameters. Results Seventy glycans were identified and their expression profiles were significantly different depending on the cyst size, the presence of an enhancing solid component, and the histological grade of the IPMN. Nine glycans were highly expressed in patients with invasive IPMNs. The glycan m/z 3195, which is a fucosylated tri-antennary glycan, had the highest diagnostic value for distinguishing invasive IPMNs from non-invasive IPMNs (area under the receiver operating characteristic curve = 0.803). Multivariate analyses revealed high levels of m/z 3195 [odds ratio (OR), 20.5; 95% confidence interval (CI) 2.60-486.4] and the presence of enhancing solid components (OR, 35.8; 95% CI, 5.39-409.6) were significant risk factors for invasive IPMNs. Conclusions We performed a comprehensive evaluation of the changes in serum N-glycan profiles in patients with IPMNs for the first time. We determined that increased expression of fucosylated complex-type glycans, especially m/z 3195, is a potential marker for invasive IPMNs.
KW - Biological markers
KW - Fucosylation
KW - Glycomics
KW - Intraductal papillary mucinous neoplasm
KW - Malignancy
KW - Pancreas
UR - http://www.scopus.com/inward/record.url?scp=84937519917&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84937519917&partnerID=8YFLogxK
U2 - 10.1016/j.pan.2015.05.470
DO - 10.1016/j.pan.2015.05.470
M3 - Article
C2 - 26052067
AN - SCOPUS:84937519917
VL - 15
SP - 432
EP - 438
JO - Pancreatology
JF - Pancreatology
SN - 1424-3903
IS - 4
ER -